skip to Main Content

  »  News  »  Medimaps Group at RSNA 2022: Providing the Full Bone-Health Picture

Providing the Full Picture of Bone Health

TBS measurements combined with BMD can offer a full “bone-health” picture by adding information on bone structure to complement bone density. Within moments, Medimaps Group’s software, TBS Insight™, provides practitioners with an easy-to-interpret score to quickly identify and classify patients’ fracture risk and implement a course of intervention. BMD tests alone miss 50% of patients who will ultimately fracture. The addition of TBS to osteoporosis screening has been shown to reduce that number by half, giving this simple $40 (USD) reimbursable test the potential to save billions in fracture and osteoporosis care.

“Our proprietary and patented TBS technology is empowered by a deep learning multi-layer approach, making it applicable for a wide spectrum of image modalities and resolutions beyond bone densitometry,” said Prof. Didier Hans, CEO of Medimaps. “TBS is demonstrating diagnostic accuracy for primary and secondary osteoporosis in females and males and also appears sensitive to changes over time as the result of either effective treatment (with TBS increasing) or continued bone loss in the absence of effective treatment (with TBS decreasing). We see the potential to seamlessly integrate and extend TBS across many clinical imaging modalities, including opportunistic X-ray based screening, patient risk profiling, cancer treatment monitoring, presurgical assessment, and more.”

Medimaps will demonstrate how their technology integrates seamlessly into the process of care, utilizing the same images acquired for BMD assessment, so patients are not exposed to additional radiation. They also will discuss how TBS:

  • Has gained international recognition with more than 900 peer-reviewed scientific publications;
  • Is included in many guidelines and used by more than 30,000 physicians worldwide, including leading healthcare institutions;
  • Aligns with physicians’ existing clinical workflows;
  • Is proven and cleared in 60+ countries;
  • Is reimbursable in the U.S. and some European countries; and
  • Can help radiologists play an even larger role in osteoporosis.

TBS Featured by Partners Hologic and GE at RSNA 2022

Medimaps Group’s TBS is integrated in Hologic’s and GE’s DXA Systems, the latest in densitometry technology, which features a complete fracture risk assessment and can capture an additional 30% of patients at fracture risk. Learn more at both GE’s and Hologic’s booths or visit Medimaps Group’s booth (#3955, AI Showcase – South Hall Level 3).

Innovation Showcase Presentation (28-November, 11:30-11:45 am CT): “Rethinking How to Diagnose Osteoporosis. Do You Have the Full Picture?”

Join us to examine the findings of a recent survey of U.S. radiologists’ perceptions of osteoporosis. 95% of radiologists surveyed underestimated the percentage of non-osteoporotic patients who fracture, and 75% underestimated that number by more than half. This presentation will also discuss how TBS—the key missing variable—when taken into account, can help to reduce the likelihood of missing patients at fracture risk.

Lynn A. Kohlmeier, MD, will host the presentation. Dr. Kohlmeier is an endocrinologist specializing in osteoporosis, parathyroid, pituitary, adrenal, and thyroid conditions. She has been involved in patient care, research, and community educational events in Spokane, Washington. She received her medical degree from Stanford University School of Medicine and has been in practice for more than 20 years.

Recent News

Back To Top